Gabriel Ling - 20 Nov 2025 Form 4 Insider Report for Oncology Institute, Inc. (TOI)

Reporting relationship: Director
Issuer ticker: TOI
Reported as of: 20 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Nov 2025, 17:23:29 UTC
Prior SEC filing: 20 Nov 2025
Next SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Gabriel Ling

Key filing fact

Gabriel Ling filed Form 4 for Oncology Institute, Inc. (TOI) on 24 Nov 2025.

Key facts

This page summarizes Gabriel Ling's Form 4 filing for Oncology Institute, Inc. (TOI).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 24 Nov 2025, 17:23.

Change

Previous filing in this sequence was filed on 20 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001945281 Primary reporting owner

Ling Gabriel

Relationship: Director
Address: C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS
Signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Gabriel Ling
Signature date: 24 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TOI transaction

Common Stock

Award

Transaction value: $0
Shares: +46,296
Change %: +19%
Price: $0.000000
Shares after: 296,502
Date: 20 Nov 2025
Ownership: Direct
Footnotes: F1

TOI transaction

Common Stock

Award

Transaction value: $0
Shares: +37,037
Change %: +12%
Price: $0.000000
Shares after: 333,539
Date: 20 Nov 2025
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date.

Footnote F2

. Represents restricted stock units that were fully vested upon grant.